Prevention of Staphylococcus aureus graft infection by a new gelatin-sealed vascular graft prebonded with antibiotics.
OBJECTIVE
The aim of this study was to evaluate the efficacy of a new gelatin-sealed graft prebonded with two antibiotics in resisting infection with Staphylococcus aureus (S aureus) A980142 after direct bacterial application in a dog model.


METHODS
Twelve 6.0-mm polyester grafts were implanted in dogs end-to-end into the infrarenal aorta. The dogs were divided into two groups. A test group (n = 6) received experimental antibiotic-bonded gelatin-sealed knitted polyester grafts, loaded with two antibiotics, rifampin and tobramycin. A control group (n = 6) received commercial gelatin-sealed knitted polyester grafts. At the end of graft implantation, 50 mul of a 1.8 x 10(4) CFU/mL S aureus solution were instilled directly over the graft. One week after implantation, grafts were harvested with sterile technique. Quantitative cultures were obtained from all the harvested grafts. The results were expressed as colony-forming units per cm(2) of surface of the graft. Bacteriological study was also performed on various tissue samples. The chi(2) test was used to compare the culture proven infection of control and antibiotics-bonded grafts.


RESULTS
Mean inoculum size was similar in the two groups of dogs. Five of the six control grafts grew S aureus A980142 at the time of graft removal, whereas none of the six antibiotic-bonded gelatin-sealed grafts were infected (P = .0192). None of the organ samples were infected in the group implanted with antibiotic-bonded grafts, whereas 15/34 samples grew S. aureus in the control group.


CONCLUSIONS
These results indicate that this gelatin sealed graft prebonded with two antibiotics resists infection caused by S aureus graft contamination in a dog model.
Javerliat
Isabelle
I
Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.
Goëau-Brissonnière
Olivier
O
Sivadon-Tardy
Valérie
V
Coggia
Marc
M
Gaillard
Jean-Louis
JL
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D001012:Aorta, Abdominal / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D004285:Dogs; D005260:Female; D005780:Gelatin; D008297:Male; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000382:microbiology; D012293:Rifampin / Q000008:administration & dosage*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D014031:Tobramycin / Q000008:administration & dosage*
D000904:Antibiotics, Antitubercular; D005780:Gelatin; D012293:Rifampin; D014031:Tobramycin